跳至主要内容
临床试验/NCT00086346
NCT00086346
终止
3 期

A Randomized, Open-Label, Comparative Evaluation of Conversion From Calcineurin Inhibitor Treatment to Sirolimus Treatment Versus Continued Calcineurin Inhibitor Treatment in Liver Allograft Recipients Undergoing Maintenance Therapy

Wyeth is now a wholly owned subsidiary of Pfizer0 个研究点目标入组 607 人2002年12月

概览

阶段
3 期
干预措施
Sirolimus (Rapamune)
疾病 / 适应症
Liver Transplantation
发起方
Wyeth is now a wholly owned subsidiary of Pfizer
入组人数
607
主要终点
Change From Baseline Adjusted Mean in Glomerular Filtration Rate (GFR)
状态
终止
最后更新
16年前

概览

简要总结

The purpose of this study is to evaluate the sirolimus conversion regimen as compared with the calcineurin inhibitor continuation regimen with regards to renal function in stable liver transplant subjects.

注册库
clinicaltrials.gov
开始日期
2002年12月
结束日期
2008年7月
最后更新
16年前
研究类型
Interventional
研究设计
Parallel
性别
All

研究者

发起方
Wyeth is now a wholly owned subsidiary of Pfizer

入排标准

入选标准

  • Age greater than 13 years (age greater than 18 years as required by some local regulations).
  • Receiving immunosuppressive therapy with calcineurin inhibitors (CI) +/- corticosteroids +/- antimetabolite.
  • 6 to 144 months after orthotopic liver transplantation.
  • Cockcroft-Gault GFR values ≥40 mL/min and ≤90mL/min at screening

排除标准

  • History of nonhepatic transplantation
  • Evidence of systemic infection (sepsis, bacteremia, pneumonia etc).
  • Known or suspected malignancy \< 5 years before random assignment.

研究组 & 干预措施

A

干预措施: Sirolimus (Rapamune)

B

干预措施: Cyclosporine or Tacrolimus

结局指标

主要结局

Change From Baseline Adjusted Mean in Glomerular Filtration Rate (GFR)

时间窗: Baseline and 12 months

GFR is an index of kidney function. GFR was calculated using Cockcroft-Gault method. A normal GFR is \>90 mL/min, higher values indicate better function. Change=adjusted mean of 12 months minus baseline. Mean adjusted for baseline GFR, with antimetabolite therapy status and hepatitis C status as fixed effects.

Patient and Graft Survival

时间窗: 12 months

Endpoint was a composite assessment of patient and graft survival. Patients categorized as graft survival or graft loss. Graft loss defined as pure graft loss (requiring retransplant) or death (with a functioning graft), if the event occurred in the first 12 months after randomization. Patients with missing graft data were counted as graft losses.

次要结局

  • Number of Patients With a Biopsy Confirmed Acute Rejection(12 months)
  • Mean Serum Creatinine(12 months)

相似试验